593 related articles for article (PubMed ID: 28607025)
1. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
[TBL] [Abstract][Full Text] [Related]
2. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
5. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of fosfomycin resistance in Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections.
Kansak N; Arıcı N; Adaleti R; Nakipoglu Y; Aksaray S
J Microbiol Methods; 2021 Sep; 188():106296. PubMed ID: 34333048
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
11. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907184
[TBL] [Abstract][Full Text] [Related]
12. Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.
Cottell JL; Webber MA
J Med Microbiol; 2019 Feb; 68(2):161-168. PubMed ID: 30543320
[TBL] [Abstract][Full Text] [Related]
13. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.
Abbott IJ; Meletiadis J; Belghanch I; Wijma RA; Kanioura L; Roberts JA; Peleg AY; Mouton JW
J Antimicrob Chemother; 2018 Mar; 73(3):709-719. PubMed ID: 29253153
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
Araj GF; Jaber FA
J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
[TBL] [Abstract][Full Text] [Related]
16. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.
So W; Crandon JL; Nicolau DP
J Urol; 2015 Aug; 194(2):563-70. PubMed ID: 25637857
[TBL] [Abstract][Full Text] [Related]
17. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
Martín-Gutiérrez G; Docobo-Pérez F; Rodriguez-Beltrán J; Rodríguez-Martínez JM; Aznar J; Pascual A; Blázquez J
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038268
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
19. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
Tutone M; Bjerklund Johansen TE; Cai T; Mushtaq S; Livermore DM
Int J Antimicrob Agents; 2022 May; 59(5):106574. PubMed ID: 35307561
[TBL] [Abstract][Full Text] [Related]
20. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
Deguchi T; Seike K; Yasuda M; Matsumoto T
J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
